Compare ACADIA Pharmaceuticals Inc. (ACAD) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while State Street Technology Select Sector SPDR ETF trades at $180.42. Which is the better fit depends on your goals.
| ACAD | XLK | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $198.21 |
52-Week Low | $20.06 | $127.49 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XLK trades at $183.60, up 1.73% with a neutral technical signal. The ETF has gained 33% year-to-date, making it the top-performing sector SPDR in 2026. Recent news highlights strong tech sector inflows and investor rotation patterns. Technical indicators show mixed signals with RSI readings in neutral territory and key support at $182.
Outlook remains positive given strong sector performance, though risks include potential Fed policy shifts and tech sector volatility. The ETF's low expense ratio and concentrated tech exposure provide competitive advantages, but investors should monitor macroeconomic indicators that could impact tech valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
